PharmaCyte Biotech, Inc.
PMCB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001157075
No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding PharmaCyte Biotech, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 33 | 32 | −1 |
| Shares | 3.53M | 1.21M | −2.31M (−65.6%) |
| Value | $10.2M | $3.47M | −$6.75M (−66.1%) |
New holders (6)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 25,874 | $74.0K | 0.00% |
| Bank of New York Mellon Corp | 16,593 | $47.5K | 0.00% |
| CSS LLC | 13,186 | $37.7K | 0.00% |
| Covestor Ltd | 189 | $1.00K | 0.00% |
| Caldwell Sutter Capital, Inc. | 2 | $6 | 0.00% |
| FMR LLC | 1 | $3 | 0.00% |
Sold out (7)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 106,886 | $311.0K |
| State Street Corp | 62,600 | $182.2K |
| Price T Rowe Associates Inc | 25,600 | $75.0K |
| Belvedere Trading LLC | 7,135 | $20.8K |
| Tower Research Capital LLC (TRC) | 505 | $1.00K |
| Advisory Services Network, LLC | 67 | $195 |
| TCI Wealth Advisors, Inc. | 3 | $9 |